Compare Invitation Homes Inc. Common Stock (INVH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invitation Homes Inc. Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? Invitation Homes Inc. Common Stock trades at $26.54 (market cap $15.68B), while Vertex Pharmaceuticals Incorporated trades at $505 (market cap $126.35B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 8.1× Invitation Homes Inc. Common Stock's market cap, and Invitation Homes Inc. Common Stock pays a 4.52% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invitation Homes Inc. Common Stock for 0 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| INVH | VRTX | |
|---|---|---|
Market Cap | $15.68B | $126.35B |
Volume | 3,619,685 | 2,089,984 |
Sector | Real Estate | Health |
52-Week High | $30.59 | $557.96 |
52-Week Low | $24.39 | $407.90 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $24.13B | $120.48B |
Dividend Yield | 4.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INVH trades at $26.59, down 0.41% on the day, with neutral technical signals and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue growth from $2.73B in 2025 to $2.9B projected for 2026 supports a solid profit margin expansion to 23.13%. Analyst consensus remains bullish with a $31.67 price target, representing 19% upside potential from current levels.
The investment case centers on INVH's consistent earnings outperformance and robust single-family rental demand, though rising interest rates pose headwinds. With 56% of analysts recommending Buy and institutional accumulation continuing, the stock offers value at current levels despite technical consolidation. Key risks include interest rate sensitivity and regulatory changes affecting institutional homebuying.
Vertex Pharmaceuticals (VRTX) trades at $485.22, down 4.3% amid a bearish technical signal, though fundamentals remain strong with 2025 revenue of $12.0B and net income of $3.95B. The company maintains dominant cystic fibrosis market position and shows positive Phase II data for kidney disease drug inaxaplin. Analyst consensus is strongly bullish with 85.7% buy ratings and $573.50 price target, representing 18% upside potential from current levels.
Vertex presents a compelling growth story with robust profitability (35% net margin) and expanding pipeline, though recent earnings misses and competitive pressures warrant caution. The stock's current dip may offer entry opportunity for long-term investors, with key catalysts including regulatory decisions and pipeline advancements expected in early 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invitation Homes Inc. Common Stock
Invitation Homes Inc. is a real estate investment trust that acquires, renovates, and leases single-family rental homes across roughly 19 US markets concentrated in Western and Southeastern US. It manages its portfolio through a pod-based local operating model supported by a maintenance technology platform.
Read more on INVH →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
